Teuvo L J Tammela

List of Publications by Year
in descending order

191	11,344	81900 39	31849 101
papers	citations	h-index	g-index

195	195	195	14392
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncology, 2022, 8, 61.	7.1	6
2	Sauna habits/bathing and changes in lower urinary tract symptoms â€“ Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology, 2022, 56, 77-82.	1.0	4
3	Populationâ€based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. BJU International, 2022, 130, 193-199.	2.5	13
4	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. Journal of Clinical Oncology, 2022, 40, 13-13.	1.6	7
5	Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 90-90.	1.6	0
6	Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes and Control, 2022, 33, 313-320.	1.8	2
7	Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. Journal of Urology, 2022, 207, 1285-1294.	0.4	6
8	Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2022, , .	6.4	1
9	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open, 2022, 12, e050264.	1.9	5
10	Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers, 2022, 14, 2920.	3.7	3
11	Prevalence of autoimmune disorders among bladder pain syndrome patientsâ€™ relatives. Scandinavian Journal of Urology, 2021, 55, 72-77.	1.0	5
12	Number of screening rounds attended and incidence of highâ€risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer, 2021, 127, 188-192.	4.1	4
13	Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. International Journal of Clinical Oncology, 2021, 26, 578-590.	2.2	9
14	Seasonal changes in occurrence and severity of lower urinary tract symptomsâ€”Tampere Aging Male Urologic Study (TAMUS). LUTS: Lower Urinary Tract Symptoms, 2021, 13, 216-223.	1.3	1
15	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. European Urology Oncology, 2021, 4, 49-55.	5.4	9
16	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	3.7	3
17	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
18	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European Urology Focus, 2021, , .	3.1	3

#	Article	IF	Citations
19	Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 239-239.	1.6	3
20	Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.. Journal of Clinical Oncology, 2021, 39, 240-240.	1.6	1
21	Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 982-989.	2.5	3
22	Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 2021, 149, 307-315.	5.1	3
23	Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer and Prostatic Diseases, 2021, 24, 1158-1166.	3.9	5
24	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 5079-5079.	1.6	3
25	Expression and ERG regulation of PIM kinases in prostate cancer. Cancer Medicine, 2021, 10, 3427-3436.	2.8	13
26	Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine, 2021, 68, 103432.	6.1	12
27	Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. Cancer Causes and Control, 2021, 32, 1299-1313.	1.8	6
28	The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patientsâ€™ spontaneous comments written in survey margins. Quality of Life Research, 2021, , 1.	3.1	2
29	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9â€‰ng/ml: long-term results from a randomized trial. Scandinavian Journal of Urology, 2021, 55, 348-353.	1.0	8
30	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	5.4	38
31	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.4	2
32	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. European Journal of Cancer, 2021, 154, 138-146.	2.8	24
33	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer. European Urology Open Science, 2021, 34, 27-32.	0.4	1
34	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	2.8	10
35	Prostate cancer risk prediction using a polygenic risk score. Scientific Reports, 2020, 10, 17075.	3.3	39
36	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. New England Journal of Medicine, 2020, 383, 1040-1049.	27.0	225

#	Article	IF	Citations
37	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	2.8	14
38	Longâ€term healthâ€related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Medicine, 2020, 9, 5643-5654.	2.8	4
39	AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene, 2020, 39, 5241-5251.	5.9	4
40	Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. Genes, 2020, 11, 314.	2.4	16
41	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE, 2020, 15, e0234269.	2.5	12
42	Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2020, 38, 5514-5514.	1.6	36
43	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
44	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
45	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
46	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
47	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. European Urology, 2019, 76, 586-595.	1.9	68
48	Risk of urothelial cancer death among people using antihypertensive drugsâ€"a cohort study from Finland. Scandinavian Journal of Urology, 2019, 53, 185-192.	1.0	5
49	Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time . Clinical Epidemiology, 2019, Volume 11, 923-932.	3.0	37
50	Evaluation of Clinically Relevant Drugâ€"Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Targeted Oncology, 2019, 14, 527-539.	3.6	60
51	Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 453-460.	3.9	11
52	Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 483-490.	3.9	6
53	Factors related to selfâ€rated health and life satisfaction one year after radical prostatectomy for localised prostate cancer: a crossâ€sectional survey. Scandinavian Journal of Caring Sciences, 2019, 33, 688-697.	2.1	8
54	Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. European Urology, 2019, 75, 1015-1022.	1.9	7

#	Article	IF	Citations
55	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	1.9	359
56	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2019, 380, 1235-1246.	27.0	621
57	Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS ONE, 2019, 14, e0224479.	2.5	6
58	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 66-76.	3.9	28
59	Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer and Prostatic Diseases, 2019, 22, 317-323.	3.9	11
60	Biasâ€corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. International Journal of Cancer, 2019, 145, 632-638.	5.1	3
61	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	1.9	131
62	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clinical Cancer Research, 2019, 25, 839-843.	7.0	7
63	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	3.1	3
64	Elevated post-void residual volume in a geriatric post-hip fracture assessment in women-associated factors and risk of mortality. Aging Clinical and Experimental Research, 2019, 31, 75-83.	2.9	8
65	A Four-kallikrein Panel and Î²-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2019, 5, 561-567.	3.1	8
66	Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. Journal of Urology, 2019, 201, 486-495.	0.4	28
67	Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 5000-5000.	1.6	16
68	ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 140-140.	1.6	5
69	Title is missing!. , 2019, 14, e0224479.		0
70	Title is missing!. , 2019, 14, e0224479.		0
71	Title is missing!. , 2019, 14, e0224479.		0
72	Title is missing!. , 2019, 14, e0224479.		0

#	Article	IF	Citations
73	Seeking certainty through narrative closure: men's stories of prostate cancer treatments in a state of liminality. Sociology of Health and Illness, 2018, 40, 639-653.	2.1	20
74	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. European Urology, 2018, 73, 870-876.	1.9	44
75	Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 373-378.	3.9	7
76	Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. European Journal of Cancer, 2018, 93, 108-118.	2.8	4
77	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naÃ¯ve and CYP17 Inhibitor-naÃ¯ve Patients: Follow-up from the ARADES and ARAFOR Trials. European Urology Focus, 2018, 4, 547-553.	3.1	30
78	Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. European Urology Focus, 2018, 4, 851-857.	3.1	5
79	Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. European Journal of Cancer Care, 2018, 27, e12729.	1.5	21
80	Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scandinavian Journal of Urology, 2018, 52, 321-327.	1.0	9
81	Severity and bother of lower urinary tract symptoms among men aged 30â€“80Âyears: Tampere Ageing Male Urological Study (TAMUS). Scandinavian Journal of Urology, 2018, 52, 296-301.	1.0	1
82	Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. Scandinavian Journal of Urology, 2018, 52, 269-276.	1.0	8
83	Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. Clinical Cancer Research, 2018, 24, 6265-6276.	7.0	17
84	ANO7 is associated with aggressive prostate cancer. International Journal of Cancer, 2018, 143, 2479-2487.	5.1	31
85	Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomyâ€”A Randomized, Double-blind, Placebo-controlled Clinical Trial. European Urology, 2018, 74, 697-701.	1.9	50
86	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. British Journal of Cancer, 2018, 119, 347-356.	6.4	63
87	Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Scientific Reports, 2018, 8, 10308.	3.3	2
88	Bladder Cancer Survival of Men Receiving 5Î±-Reductase Inhibitors. Journal of Urology, 2018, 200, 743-748.	0.4	22
89	Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell, 2018, 174, 576-589.e18.	28.9	116
90	Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. Annals of Diagnostic Pathology, 2018, 35, 80-84.	1.3	1

#	Article	IF	Citations
91	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
92	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
93	Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.. Journal of Clinical Oncology, 2018, 36, 30-30.	1.6	0
94	What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiology, 2017, 46, 14-19.	1.9	3
95	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. Journal of Urology, 2017, 198, 50-57.	0.4	24
96	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2017, 51, 5-12.	1.0	41
97	Outcomes of Prostate Cancer Screening by 5Î±-Reductase Inhibitor Use. Journal of Urology, 2017, 198, 305-309.	0.4	3
98	The effect of nonâ€steroidal antiâ€inflammatory drugs on risk of benign prostatic hyperplasia. Prostate, 2017, 77, 1029-1035.	2.3	8
99	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	6.4	99
100	Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 544.e25-544.e31.	1.6	9
101	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naÃ¯ve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. European Urology Focus, 2017, 3, 606-614.	3.1	18
102	Components of metabolic syndrome and prognosis of renal cell cancer. Scandinavian Journal of Urology, 2017, 51, 435-441.	1.0	10
103	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	5.7	36
104	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. Journal of Urology, 2017, 198, 1333-1339.	0.4	7
105	High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. Scandinavian Journal of Urology, 2017, 51, 367-372.	1.0	11
106	A genetic variant nearGATA3implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Prostate, 2017, 77, 1213-1220.	2.3	19
107	Enzalutamide in Men with Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology, 2017, 71, 151-154.	1.9	306
108	Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2017, 3, 212-220.	3.1	37

#	Article	IF	Citations
109	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Scientific Reports, 2017, 7, 17978.	3.3	38
110	Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. BMC Cancer, 2017, 17, 585.	2.6	9
111	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. PLoS ONE, 2016, 11, e0150241.	2.5	28
112	Amplification of the 9p13.3 chromosomal region in prostate cancer. Genes Chromosomes and Cancer, 2016, 55, 617-625.	2.8	14
113	5â€Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. International Journal of Cancer, 2016, 138, 2820-2828.	5.1	14
114	Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate, 2016, 76, 469-478.	2.3	17
115	Germline copy number variation analysis in Finnish families with hereditary prostate cancer. Prostate, 2016, 76, 316-324.	2.3	14
116	Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based caseâ€“control study. Cancer Causes and Control, 2016, 27, 637-645.	1.8	13
117	Intravesical Bacillus Calmette-GuÃ©rin Versus Combination of Epirubicin and Interferon-Î±2a in Reducing Recurrence of Nonâ€“Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. European Urology, 2016, 70, 341-347.	1.9	23
118	Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. Urology, 2016, 95, 164-170.	1.0	6
119	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. European Urology, 2016, 70, 499-505.	1.9	6
120	Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. Cancer Epidemiology, 2016, 45, 1-5.	1.9	14
121	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian Journal of Urology, 2016, 50, 413-419.	1.0	14
122	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
123	Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. Biochemical and Biophysical Research Communications, 2016, 481, 46-50.	2.1	23
124	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349.	2.9	8
125	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
126	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	3.8	37

#	Article	IF	Citations
127	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. European Urology, 2016, 69, 834-840.	1.9	49
128	Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 372-381.	1.9	20
129	Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. Genes Chromosomes and Cancer, 2016, 55, 661-673.	2.8	5
130	The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. European Journal of Pharmacology, 2016, 788, 160-167.	3.5	20
131	Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scandinavian Journal of Urology, 2016, 50, 267-273.	1.0	30
132	Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). European Urology, 2016, 69, 720-727.	1.9	41
133	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249.	7.0	35
134	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.. Journal of Clinical Oncology, 2016, 34, 5001-5001.	1.6	11
135	ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, TPS5094-TPS5094.	1.6	1
136	Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. PLoS ONE, 2016, 11, e0153413.	2.5	18
137	Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.. Journal of Clinical Oncology, 2016, 34, e16599-e16599.	1.6	0
138	Epigenetically altered miRâ€193b targets cyclin D1 in prostate cancer. Cancer Medicine, 2015, 4, 1417-1425.	2.8	39
139	Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. Prostate, 2015, 75, 1394-1402.	2.3	19
140	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
141	MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families. PLoS ONE, 2015, 10, e0127427.	2.5	9
142	Sotalol, but not digoxin is associated with decreased prostate cancer risk: A populationâ€based caseâ€“control study. International Journal of Cancer, 2015, 137, 1187-1195.	5.1	21
143	Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. European Journal of Cancer, 2015, 51, 1283-1292.	2.8	18
144	Muraglitazar-Eluting Bioabsorbable Vascular Stent Inhibits Neointimal Hyperplasia in Porcine Iliac Arteries. Journal of Vascular and Interventional Radiology, 2015, 26, 124-130.	0.5	6

#	Article	IF	Citations
145	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	1.9	111
146	Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. European Urology, 2015, 68, 1089-1097.	1.9	7
147	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
148	Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. Cancer Research, 2015, 75, 4026-4031.	0.9	68
149	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27
150	Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS). European Urology, 2015, 67, 482-491.	1.9	106
151	Long-term survival update of the Scandinavian Prostate Cancer Group 6 study: Bicalutamide 150 mg daily versus placebo in hormone-naÃ¯ve, non-metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 2-2.	1.6	1
152	Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.. Journal of Clinical Oncology, 2015, 33, 230-230.	1.6	2
153	Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget, 2015, 6, 6235-6250.	1.8	23
154	ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2015, 33, TPS5080-TPS5080.	1.6	0
155	Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis. PLoS ONE, 2014, 9, e89508.	2.5	7
156	What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. European Urology, 2014, 65, 1211-1217.	1.9	193
157	Natural Course of Lower Urinary Tract Symptoms in Men Not Requiring TreatmentÂâ€“ÂA 5-Year Longitudinal Population-based Study. Urology, 2014, 83, 411-415.	1.0	7
158	Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2014, 65, 1046-1055.	1.9	709
159	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology, The, 2014, 15, 975-985.	10.7	172
160	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	13.7	1,261
161	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
162	Detection of Prostate Cancer by an Electronic Nose: A Proof of Principle Study. Journal of Urology, 2014, 192, 230-235.	0.4	72

#	Article	IF	Citations
163	Modeling and Analysis of Gleason Score 8-10 Prostate Cancers in the REDUCE Study. Urology, 2014, 84, 393-399.	1.0	5
164	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
165	A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 115-115.	1.6	3
166	Rapid and Accurate Detection of Urinary Pathogens by Mobile IMS-Based Electronic Nose: A Proof-of-Principle Study. PLoS ONE, 2014, 9, e114279.	2.5	35
167	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	8
168	The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth. PLoS ONE, 2012, 7, e39445.	2.5	69
169	Endocrine prevention and treatment of prostate cancer. Molecular and Cellular Endocrinology, 2012, 360, 59-67.	3.2	23
170	The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based caseâ€“control study. Cancer Causes and Control, 2011, 22, 1445-1452.	1.8	23
171	Six-year follow-up and predictors of urgency-associated urinary incontinence and bowel symptoms among the oldest old: A population-based study. Archives of Gerontology and Geriatrics, 2009, 49, e85-e90.	3.0	24
172	Endocrine treatment of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 287-295.	2.5	84
173	Androgen receptor CAG polymorphism and prostate cancer risk. Human Genetics, 2002, 111, 166-171.	3.8	61
174	PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCER. Journal of Urology, 2001, 165, 1569-1574.	0.4	9
175	Biocompatibility of silver nitrate and ofloxacine coated bioabsorbable SR-PLLA rods. Urological Research, 2001, 29, 113-117.	1.5	6
176	Bacterial adherence to silver nitrate coated poly- L -lactic acid urological stents in vitro. Urological Research, 2000, 28, 327-331.	1.5	18
177	Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2744-2747.	3.6	63
178	Association of Dietary Elements and Lower Urinary Tract Symptoms. Scandinavian Journal of Urology and Nephrology, 2000, 34, 46-50.	1.4	26
179	Cytotoxicity testing of a new caprolactone-coated self-expanding bioabsorbable self-reinforced poly-l-lactic acid urethral stent. Urological Research, 1999, 27, 149-152.	1.5	11
180	Duration of increased mucosal permeability of the urinary bladder after acute overdistension: an experimental study in rats. Urological Research, 1999, 27, 272-276.	1.5	20

#	Article	IF	Citations
181	Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer. Journal of Clinical Oncology, 1999, 17, 2859-2859.	1.6	439
182	Evidence for a prostate cancer susceptibility locus on the X chromosome.. Nature Genetics, 1998, 20, 175-179.	21.4	641
183	CYP1A1 activity in renal cell carcinoma and in adjacent normal renal tissue. Urological Research, 1998, 26, 117-121.	1.5	10
184	Influence of Transient Overdistension on Bladder Wall Morphology and Enzyme Histochemistry. Scandinavian Journal of Urology and Nephrology, 1997, 31, 517-522.	1.4	9
185	Benign Prostatic Hyperplasia. Drugs and Aging, 1997, 10, 349-366.	2.7	59
186	Effect of Concomitant Administration of Clodronate and Estramustine Phosphate on their Bioavaibility in Patients with Metastasized Prostate Cancer. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 157-160.	0.0	2
187	Preservation of Potency after Treatment for Priapism. Scandinavian Journal of Urology and Nephrology, 1996, 30, 313-316.	1.4	40
188	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics, 1995, 9, 401-406.	21.4	1,316
189	Priapism, its Incidence and Seasonal Distribution in Finland. Scandinavian Journal of Urology and Nephrology, 1995, 29, 93-96.	1.4	65
190	Malignant Fibrous Histiocytoma of the Prostate. Scandinavian Journal of Urology and Nephrology, 1994, 28, 429-431.	1.4	11
191	Urothelial permeability of the isolated whole bladder. Neurourology and Urodynamics, 1993, 12, 39-47.	1.5	33